Study on visfatin-induced inflammation and necroptosis via LOX-1 in human umbilical vein endothelial cells

The aim of the study is to identify the effects and underlying mechanisms of visfatin on inflammation and necroptosis in vascular endothelial cells. Human umbilical vein endothelial cells (HUVECs) were stimulated with visfatin or pretreated with Polyinosinic acid (LOX-1 inhibitor). By using the Western blot, RT-PCR, immunocytochemistry, enzyme-linked immunosorbent assay (ELISA), MTT and flow cytometry technique, the occurrence of inflammation and necroptosis in HUVECs were evaluated. Our results showed that 100 ng/mL visfatin significantly increased the mRNA and protein expression of monocyte chemotactic protein 1 (MCP-1) and LOX-1 after 24 hours' treatment in HUVECs. However, pretreatment with Polyinosinic acid could significantly reduce the expression of MCP-1 compared with visfatin group. Additionally, 100 ng/mL visfatin could induce the production of necrotic features and increase the mRNA expression of BMF (one of the markers of necroptosis), while pretreating with Polyinosinic acid markedly downregulated the mRNA expression of BMF gene and promoted the cell proliferation. These results indicate that visfatin might induce inflammation and necroptosis via LOX-1 in HUVECs, suggesting that visfatin plays a central role in the development of atherosclerosis.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:37

Enthalten in:

Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi - 37(2020), 5 vom: 25. Okt., Seite 834-841

Sprache:

Chinesisch

Beteiligte Personen:

Han, Xiaoyu [VerfasserIn]
Wu, Wenchao [VerfasserIn]
Liu, Xiaojing [VerfasserIn]
Zhu, Ye [VerfasserIn]

Links:

Volltext

Themen:

EC 2.4.2.12
Human umbilical vein endothelial cells
Inflammation
Journal Article
LOX-1
Necroptosis
Nicotinamide Phosphoribosyltransferase
OLR1 protein, human
Scavenger Receptors, Class E
Visfatin

Anmerkungen:

Date Completed 15.01.2021

Date Revised 09.08.2023

published: Print

Citation Status MEDLINE

doi:

10.7507/1001-5515.202003067

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM317089129